AVACOPAN | AVACOPAN : Antagonist of C5AR1
RATINGS:
Cellular Use: (3 reviews)

In Model Organisms: (3 reviews)
Control Compounds

Probe Summary

Targets Biochemical/Biophysical Potency Cellular Potency
C5AR1
    • IC50:0.1 nM
    • IC50:0.2 nM
    • IC50:0.1 nM
    Antagonist
    up to 100 nM

    Selectivity

    In Vitro Selectivity Assessment
    Potency Assay Off-Target:
    CCX168 is selective for C5aR, with no activity (IC50 >5,000 nM) measured with the C5aR-related recep ...

    Potency
    Cellular
    In Vitro

    C5AR1

    Mode of Action: Antagonist

    Structure-Activity-Relationship data available? No

    DOI Reference: 10.1371/journal.pone.0164646

    In Vivo Validations

    Mouse
    Dose: 0.5 mg/Kg
    Route of delivery: Intravenous
    Plasma half life: 1.8 h
    Systemic clearance: 26.6 mL/min/kg
    Volume of Distribution at Steady-State: 1.5 L/Kg

    DOI Reference: 10.1371/journal.pone.0164646

    Dose: 2 mg/Kg
    Route of delivery: Oral
    Cmax: 75 ng/mL
    Tmax: 1.0 h
    Area Under the Curve:: 240 ng•h/mL
    Bioavailability: 17%

    DOI Reference: 10.1371/journal.pone.0164646

    Dose: 30 mg/Kg
    Route of delivery: Oral
    Plasma half life: 5.6 h
    Cmax: 4630 ng/mL
    Tmax: 1.0 h
    Area Under the Curve:: 18600 ng•h/mL
    Bioavailability: 87%

    DOI Reference: 10.1371/journal.pone.0164646

    Rat
    Dose: 0.5 mg/Kg
    Route of delivery: Intravenous
    Plasma half life: 1.9 h
    Systemic clearance: 21.2 mL/min/kg
    Volume of Distribution at Steady-State: 1.8 L/Kg

    DOI Reference: 10.1371/journal.pone.0164646

    Dose: 2 mg/Kg
    Route of delivery: Oral
    Plasma half life: 2.3 h
    Cmax: 152 ng/mL
    Tmax: 1.0 h
    Area Under the Curve:: 464 ng•h/mL
    Bioavailability: 27%

    DOI Reference: 10.1371/journal.pone.0164646

    Dose: 30 mg/Kg
    Route of delivery: Oral
    Plasma half life: 4.6 h
    Cmax: 2530 ng/Kg
    Tmax: 1.5 h
    Area Under the Curve:: 24600 ng•h/mL
    Bioavailability: 104%

    DOI Reference: 10.1371/journal.pone.0164646

    Dog
    Dose: 0.5 mg/Kg
    Route of delivery: Intravenous
    Plasma half life: 14.2 h
    Systemic clearance: 11.9 mL/min/kg
    Volume of Distribution at Steady-State: 4.7 L/Kg

    DOI Reference: 10.1371/journal.pone.0164646

    Monkey (Cynomolgus)
    Dose: 100 mg/Kg
    Route of delivery: Oral
    Plasma half life: 6.0 h
    Cmax: 3500 ng/Kg
    Tmax: 4.0 h
    Area Under the Curve:: 33300 ng•h/mL

    DOI Reference: 10.1371/journal.pone.0164646

    Chemical Information

    Molecular Formula C33H35F4N3O2
    SMILEs Cc1ccc(NC(=O)[C@H]2CCCN(C(=O)c3c(C)cccc3F)[C@H]2c2ccc(NC3CCCC3)cc2)cc1C(F)(F)F
    InChI InChI=1S/C33H35F4N3O2/c1-20-12-15-25(19-27(20)33(35,36)37)39-31(41)26-10-6-18-40(32(42)29-21(2)7-5-11-28(29)34)30(26)22-13-16-24(17-14-22)38-23-8-3-4-9-23/h5,7,11-17,19,23,26,30,38H,3-4,6,8-10,18H2,1-2H3,(H,39,41)/t26-,30-/m0/s1
    Molecular weight 581.27 Da
    AlogP 8.04804
    HBond acceptors 5
    HBond donors 2
    Atoms 77

    Vendors

    Note: This is not an exhaustive list and does not indicate endorsement by the portal.

    Expert Reviews


    (on 11 Oct 2022 )
    Cellular Use Rating
    In Model Organisms
    A clinical compound targeting complement 5a Receptor (C5aR). It is potent and selective, however, displays reduced activity on C5aR from most model species, including mice, rats, and rabbits. For PD studies,...
    (on 31 Oct 2022 )
    Cellular Use Rating
    In Model Organisms
    Avacopan (CCX168) is a selective antagonist of the human complement 5a receptor (C5aR1 or CD88) and competitively inhibits the interaction between the receptor and the anaphylatoxin C5a, a terminal component...
    (on 14 Oct 2025 )
    Cellular Use Rating
    In Model Organisms
    In the cellular experiments, no positive or negative controls were provided. Given the advancement to clinical trials, it can be safely assumed that cytotoxicity of this compound is negligible. There are...
    Note: The Chemical Probes Portal only endorses compounds as chemical probes for use as specific and selective modulators of the proposed target if they receive three or more (3-4) stars. Read more about our evaluation criteria